Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
3
38%
Ph phase_1
3
38%
Ph phase_2
2
25%

Phase Distribution

3

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 22 (25.0%)
Phase 33 (37.5%)

Trials by Status

completed675%
terminated113%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

NCT04540419
terminatedphase_3

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

NCT05169008
completedphase_3

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

NCT04526990
completedphase_2

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

NCT04341389
completedphase_1

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

NCT04840992
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04540419Phase 3

Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

Completed
NCT05169008Phase 3

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents

Terminated
NCT04526990Phase 3

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

Completed
NCT04341389Phase 2

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)

Completed
NCT04840992Phase 1

Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation

Completed
NCT04566770Phase 2

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Completed
NCT04313127Phase 1

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

Completed
NCT04398147Phase 1

Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada

Unknown

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8